After the completion or termination of a clinical trial, who should store the enrollment log?
Correct Answer: A
The Principal Investigator (PI) is responsible for maintaining and securely storing essential documents, including the enrollment log, after the completion or termination of a clinical trial. This ensures that all participant-related records are retained for audit or inspection as per regulatory requirements. This answer is consistent with GCP guidelines, which specify that the PI is accountable for retaining essential trial documents at the study site. "The investigator should maintain records of trial participants, including the enrollment log, as part of the essential documents for trial conduct." Objectives: * Maintain data integrity and compliance with record-keeping requirements. * Ensure secure and accessible storage of participant information.
Question 12
Prior to initiation of a clinical trial, review by an IRB/IEC is required for which of the following documents?
Correct Answer: C
Before a clinical trial can begin, the IRB/IEC must review the protocol, Investigator's Brochure (IB), and any information related to payments and compensation. This review ensures that the study is ethically sound, scientifically valid, and that participants are informed about any financial considerations. GCP guidelines specify that essential documents, including the protocol, IB, and compensation details, must be reviewed by the IRB/IEC to maintain ethical oversight. "The IRB/IEC must evaluate the protocol, IB, and any financial disclosures to ensure ethical compliance and participant protection." Objectives: * Guarantee ethical oversight in clinical trial conduct. * Protect participants through informed consent and transparency.
Question 13
Source data/documentation should be:
Correct Answer: A
Source data/documentation in clinical trials must meet the ALCOA-C standard: Attributable, Legible, Contemporaneous, Original, Accurate, and Complete. This ensures that data is credible, traceable to the source, and maintains integrity throughout the study. These attributes are essential for maintaining high- quality, reliable, and verifiable clinical trial records. GCP guidelines mandate that source documentation should adhere to the ALCOA-C principles to maintain data integrity and reliability. "Source data must be attributable, legible, contemporaneous, original, accurate, and complete to meet quality and compliance standards." Objectives: * Maintain data integrity and reliability. * Adhere to best practices in clinical documentation.
Question 14
During a multi-center, double-blind, placebo-controlled Phase III clinical trial evaluating a novel oncology drug, the following situation occurs: An interim analysis performed by the DSMB reveals that the investigational product (IP) shows a statistically significant improvement in progression-free survival (PFS) compared to the placebo. However, a sub-group analysis indicates a higher incidence of Grade 4 hepatotoxicity in patients with pre-existing mild liver dysfunction. The sponsor, upon reviewing the DSMB report, decides to unblind the affected sub-group to assess safety. The trial protocol specifies that unblinding should only occur if a life-threatening situation is identified. What is the most appropriate next step the sponsor should take?
Correct Answer: D
In this situation, the correct course of action is to request the DSMB to conduct a thorough risk assessment and provide recommendations on unblinding the affected sub-group. * Reasoning: * The trial protocol specifies that unblinding should only occur if a life-threatening situation arises. Since the observed hepatotoxicity, although severe, does not automatically qualify as life- threatening, it is prudent to proceed cautiously. * Immediate unblinding of the entire trial (Option A) would compromise the study's integrity and could introduce bias. * Submitting the DSMB findings to the IRB/IEC (Option B) without first conducting a more thorough risk assessment may delay necessary safety measures. * Conducting a protocol amendment (Option C) without a comprehensive risk assessment may be premature. * Role of the DSMB: * The DSMB is responsible for evaluating safety data and making independent recommendations to protect trial participants. In this case, the DSMB should analyze the risk/benefit ratio of continuing the trial with the current protocol versus implementing safety modifications. * Ethical Considerations: * Protecting patient safety is paramount, but any unblinding must be justified by a clear and imminent risk. The DSMB's independent judgment is critical to making this decision without sponsor influence. Verified Answer from Official Source: According to GCP guidelines, any decision to unblind a study must be based on a comprehensive safety assessment, and the DSMB plays a key role in making unbiased recommendations regarding unblinding. Exact Extract: "Unblinding in a clinical trial should only occur when justified by critical safety concerns, as recommended by an independent data monitoring committee." Objectives: * Maintain trial integrity while safeguarding patient safety. * Follow protocol and regulatory requirements for unblinding. * Ensure independent decision-making by the DSMB to avoid sponsor bias.
Question 15
While reviewing reports of data completion, the sponsor notices low retention rates at many participating sites. What is an appropriate FIRST action for the sponsor to take?
Correct Answer: D
Meeting with site staff to understand workflows and retention strategies is the most practical first step. By engaging with the team, the sponsor can identify potential issues affecting retention, such as site-related factors, participant burden, or protocol complexities. Addressing these issues collaboratively can improve retention without needing major protocol changes. GCP guidelines recommend assessing and understanding site-specific challenges before making procedural changes or protocol amendments. "Engaging with site staff to discuss retention issues helps identify root causes and develop practical solutions." Objectives: * Improve participant retention through collaboration. * Identify and address site-specific challenges.
